WO1999040442A1 - Dosage des troponines sans interferences dues a l'heparine - Google Patents
Dosage des troponines sans interferences dues a l'heparine Download PDFInfo
- Publication number
- WO1999040442A1 WO1999040442A1 PCT/FR1999/000198 FR9900198W WO9940442A1 WO 1999040442 A1 WO1999040442 A1 WO 1999040442A1 FR 9900198 W FR9900198 W FR 9900198W WO 9940442 A1 WO9940442 A1 WO 9940442A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- heparin
- troponin
- tnl
- polybrene
- cardiac
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- the present invention relates to a method for assaying troponins in biological media making it possible to avoid interference due to heparin.
- troponin is a myofib llar protein complex, made up of three proteins, troponins I, T and C. This protein complex helps to regulate muscle contraction by the Ca 2+ ion, interacting with myosin and actin. More precisely, it is known that when a nerve impulse arrives at the level of the motor plaque of a muscle, there is generation of an action potential which is transmitted to the sarcoplasmic reticulum. Ca 2+ is then released into the cytosol and binds to troponin C, which leads to a strengthening of the interaction between troponin I and troponin C and, consequently, a change in conformation of the troponin I, T complex. , C. There is then release of the actin-myosin interaction sites, which allows the muscle to contract.
- the muscle When the muscle is damaged, irreversibly, it is the heart muscle, during myocardial necrosis following a myocardial infarction, or it is the skeletal muscle during prolonged physical exertion, the released troponins appear (more or less quickly) into the bloodstream.
- the dosage of troponin has recently been advocated for the early diagnosis of myocardial infarction, whether that of troponin T in Circulation (1991,) 83, pp. 902-912, or troponin I in Am. Heart J. (1987), VW, pp. 1333-1344, and Molecular Immunology (1992), 29 (2). pp. 271-278.
- the assay of cardiac troponin T has been proposed to measure the success of thrombolytic therapy following a myocardial infarction in Br. Heart J., (1994), T ⁇ , pp. 242-248, as well as the assay of skeletal troponin I for the measurement of skeletal muscle damage (D. Rama et al, Clinical Chemistry (1996), 42 n "12. p. 2033). It should be noted that the dosage of
- heparin-containing equipment heparinized tubes, etc.
- heparin in addition, before angioplasty or after a myocardial infarction or during certain treatments for cardiovascular conditions, patients are administered significant amounts of heparin and this treatment is often extended beyond 24 hours. Depending on the dose administered, the concentration of heparin in the plasma one hour after administration can vary between 0.1 to 2 IU / ml. The presence of heparin in the blood samples due to the treatment of the patient constitutes an important problem for the dosage of troponins. - 3 -
- the present invention relates more specifically to an immunological assay method for troponin I (cardiac or skeletal), T or C, and troponins I, T or C associated together in the form of dimers (IT, IC or TC) or in the form trimer (ITC) in a biological sample containing heparin, characterized in that the immunoassay is carried out in the presence of hexadimethrin bromide (polybrene).
- hexadimethrin bromide polybrene
- the amount of polybrene used during the immunoassay of troponin I (cardiac or skeletal), T or C, and troponins I, T or C associated with one another in the form of dimers (IT, IC or TC) or under Trimer form (ITC) may vary depending on the immunoassay procedure used.
- the ratio [molar concentration of the polybrene used / molar concentration of heparin present in the sample to be analyzed] can be from 1 to 1000. Depending on the dosage, it can more specifically be - 4 -
- the polybrene can be added directly to the biological sample containing or likely to contain heparin or it can be further added to one of the immunoassay reagents such as buffer solutions, solution of the conjugate reagent, etc. It is preferred to add the polybrene in buffer solutions used during the immunoassay.
- buffer solution includes any solution used in the early immunoassay steps present with the plasma sample. Washing solutions are excluded from this term.
- the present invention can be implemented with any immunological method allowing the evaluation of troponin I (cardiac or skeletal), T or C, and troponins I, T or C associated with one another in the form of dimers (IT, IC or TC) or in the form of trimer (ITC).
- troponin I cardiac or skeletal
- T or C troponins I, T or C associated with one another in the form of dimers (IT, IC or TC) or in the form of trimer (ITC).
- immunoenzymatic methods are preferred which allow the determination of troponin I (cardiac or skeletal), T or C or of dimers or trimers thereof in a biological sample, which use polybrene to suppress interference due to heparin.
- the sandwich type methods are preferred.
- the sandwich type processes can be carried out in one or more stages (two stages, three stages etc.) and use two or more monoclonal or polyclonal antibodies.
- Patent application WO 96/22535 also describes an immunoenzymatic assay method of the sandwich type allowing the quantitative assay of the cardiac troponin I
- This method uses for the enzymatic revelation a chemiluminescent substrate, chosen from derivatives of a diacylhydrazine, ie a derivative of 1, 2-d ⁇ oxetane and can be carried out either by a manual system (diagnostic assay kit) or by an automated system Depending on the embodiment, it is possible to carry out either a one-time dosage or a two time
- a kit allowing the immunoenzymatic assay of troponin T is also commercially available. It is the kit "Troponine T / ES 300 Analyzer” marketed by Boeh ⁇ nger Mannheim, Mannheim Germany (N Genser et al, Clin. Chem Acta (1997). ), 265, pp. 207-217, H Baum et al, Clin Chem (1997), 43/10, p 1877-1977) - 6 -
- Patent application WO 96/33415 also describes sandwich-type immunoassays for evaluating the amounts of troponins I and T or of troponin I, C and or T complexes in biological media
- the method according to the invention can be applied as indicated above to any type of troponin immunological method
- the method according to the invention can be applied during immunoassays (for example as described by C Lame et al in L'Information cardiohack (1991) vol XV n "1. pp 17-21) and fluoroimmunoassays (L Bellanger et al, Clin Chem (1997), vol 43 n ° 6. p S159, n ° 240)
- troponin I cardiomyalpha-1 (cardiac or skeletal), T or C, and troponins I, T or C associated together in the form of dimers (IT, IC or TC) or in the form of trimer (ITC), to avoid interference due to heparin is part of the present invention
- the invention also relates to immunoassay kits for troponin I (cardiac or skeletal), T or C and troponins I, T or C associated between - 7 -
- dimers in the form of dimers (IT, IC or TC) or in the form of trimer (ITC), containing among the immunoassay reagents polybrene.
- heparin lithium heparinase I
- heparinase I heparinase I from Flavobacterium heparinum Sigma ref. H 2519
- L-histidine Sigma ref. H 8000
- protamine sulfate protamine sulfate grade X from salmon Sigma ref. P 4020
- antithrombin III antithrombin III from huma ⁇ plasma Sigma ref. A 7388
- cation exchange resins QSFF (Q Sepharose Fast Flow, Pharmacia Biotech ref. 17051001) and DEAE (DEAE Sepharose Fast Flow, Pharmacia Biotech ref. 17070901).
- the automated system used for the enzyme immunoassay is the Access® immunoassay system, system marketed by Beckman.
- the kit used is the Access-Troponin I kit, marketed by the same company.
- the assay is carried out as follows: into the assay cup are introduced 50 ⁇ l of the sample to be assayed, 25 ⁇ l of a solution - 8 -
- mouse immunoglobulin 4 mg / ml 10 ⁇ l of a 0.1 M succinic acid solution containing the heparin inhibitor and 50 ⁇ l of the mouse cardiac anti-troponin I monoclonal antibody conjugate 8E1 -phosphatase alkaline (concentration: 5 ⁇ g / ml). After incubation for 5 minutes at 37 ° C., 50 ⁇ l of ferric latex beads are introduced (Rhône Poulenc ref. MI-070/60) to which are fixed by covalent bonds monoclonal anti-troponin I cardiac antibodies of mice 11 E12 .
- the cardiac anti-troponin I antibodies of mouse heart 8E1 and 11 E12 are part of the Troponin I kit.
- the mixture is incubated for 36 seconds at 37 ° C., then the ferric latex beads are separated using a magnetic field.
- the washing is carried out using a Tris pH 8 buffer solution, then 200 ⁇ l of Lumi-Phos® 530 substrate are added. This substrate is also part of the Access-Troponin I kit.
- the development is carried out at 37 ° C. and the luminescence generated by the reaction is measured with a luminometer.
- the total analysis time is 15 minutes.
- a calibration range is carried out corresponding to concentrations between 0 and 50 ⁇ g / l.
- Heparinase I heparinase I 2 IU / mI 7 IU / ml
- the Troponine I Pasteur kit was used (Sanofi Diagnostics Pasteur, Marnes-la Coquette, France). The assay is carried out as follows:
- 150 ⁇ l of a succinate buffer solution comprising polybrene and containing 0.2% Tween® 20, mouse immunoglobulins, are introduced into polystyrene tubes coated with 8E1 mouse cardiac anti-troponin I monoclonal antibodies. non-specific and 0.1% Kathon®, 50 ⁇ l of the anti-troponin I monoclonal antibody conjugate mouse heart 1 1 E12- peroxidase, and 200 ⁇ l of sample to be assayed or of a standard solution used for the range of calibration.
- human serum containing from 0 to 1.74 ⁇ g / l of purified human cardiac troponin I is used.
- washing is carried out by adding 1 ml of 0.1 M phosphate buffer, pH 6.8 containing 0.1% Tween® 20 and 0.3% Kathon, keeping the temperature of the washing solution at most 8 ° C. This step is repeated 4 times.
- the enzymatic development is carried out using 600 ⁇ l of a mixture consisting of 1 part of tetramethylbenzydine and 100 parts of citrate buffer containing 4% DMSO and 0, 03% hydrogen peroxide.
- Tnl positive serum + diluent 1 160 1,240 Tnl positive serum + heparin 40IU / ml 0.480 1.170
- the troponin I assay is performed with the Troponine I Pasteur kit (Sanofi Diagnostics Pasteur, Marnes-la Coquette, France).
- the automated system used for the enzyme immunoassay is the Access® immuoassay system, a system marketed by Beckman.
- the immunoassay method is that described in Example I.
- Plasmas from five patients containing heparin were analyzed. The results of this study are given in Table VIII. From this study it emerges that when the automated system described above for the determination of Troponin I is used, it is necessary to use from 60 to 120 mol of polybrene per mol of heparin present in the sample.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99901673A EP1051623A1 (fr) | 1998-02-05 | 1999-02-01 | Dosage des troponines sans interferences dues a l'heparine |
JP2000530804A JP2002502979A (ja) | 1998-02-05 | 1999-02-01 | ヘパリンによる干渉なしのトロポニンアッセイ |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR98/01367 | 1998-02-05 | ||
FR9801367A FR2774473B1 (fr) | 1998-02-05 | 1998-02-05 | Procede de dosage des troponines dans des milieux biologiques permettant d'eviter les interferences dues a l'heparine |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999040442A1 true WO1999040442A1 (fr) | 1999-08-12 |
Family
ID=9522644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1999/000198 WO1999040442A1 (fr) | 1998-02-05 | 1999-02-01 | Dosage des troponines sans interferences dues a l'heparine |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1051623A1 (fr) |
JP (1) | JP2002502979A (fr) |
FR (1) | FR2774473B1 (fr) |
WO (1) | WO1999040442A1 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002063302A1 (fr) * | 2001-02-07 | 2002-08-15 | Immunomatrix Inc. | Technique permettant de reduire l'interference de l'heparine dans des essais diagnostic de la troponine cardiaque |
JP2004510161A (ja) * | 2000-09-25 | 2004-04-02 | アボット・ラボラトリーズ | 高分子ポリカチオンを用いることにより、特異的結合アッセイにおける血清または血漿含有アッセイ試料の干渉を減少させるための方法及びキット |
CN108291911A (zh) * | 2015-10-30 | 2018-07-17 | 美迪恩斯生命科技株式会社 | 凝血酶-抗凝血酶复合体的测定试剂及测定方法 |
US10627393B2 (en) | 2012-07-31 | 2020-04-21 | Sekisui Medical Co., Ltd. | Latex agglutination inhibition immunoassay |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090317843A1 (en) * | 2006-12-22 | 2009-12-24 | Alberto Mantovani | Method for measuring plasma levels of long pentraxin ptx3 |
JP5334742B2 (ja) * | 2009-08-11 | 2013-11-06 | 関東化学株式会社 | 水溶性アンモニウムポリマーを含有する検体前処理試薬、および検体前処理方法 |
CN103380377B (zh) * | 2011-02-25 | 2016-01-27 | 美迪恩斯生命科技株式会社 | 心肌肌钙蛋白的测定方法 |
CN102426246A (zh) * | 2011-08-31 | 2012-04-25 | 内蒙古科慧生物科技有限责任公司 | 人肌钙蛋白I(Troponin I)定量测定试剂盒及其检测方法 |
KR102228440B1 (ko) | 2016-04-13 | 2021-03-15 | 가부시키가이샤 엘에스아이 메디엔스 | 황산화 다당류를 이용한 면역학적 측정법 |
-
1998
- 1998-02-05 FR FR9801367A patent/FR2774473B1/fr not_active Expired - Fee Related
-
1999
- 1999-02-01 JP JP2000530804A patent/JP2002502979A/ja active Pending
- 1999-02-01 WO PCT/FR1999/000198 patent/WO1999040442A1/fr not_active Application Discontinuation
- 1999-02-01 EP EP99901673A patent/EP1051623A1/fr not_active Withdrawn
Non-Patent Citations (7)
Title |
---|
A H B WU, R VALDES, F S APPLE, T GORNET, M A STONE, S MAYFIELD-STOKES, A M INGERSOLL-STROUBOS, B WILER: "Cardiac Troponin-T Immunoassay for Diagnosis of Acute Myocardial Infarction", CLINICAL CHEMISTRY, vol. 40, no. 6, June 1994 (1994-06-01), pages 900 - 907, XP002086288 * |
A H B WU, Y-J FENG, R MOORE, F S APPLE, P H MCPHERSON, K F BUECHLER, G BODOR: "Charcterization of cardiac troponin subunit release into serum after acute myocardial infarction and comparison of assays for troponin T and I", CLINICAL CHEMISTRY, vol. 44, no. 6, June 1998 (1998-06-01), pages 1198 - 1208, XP002086287 * |
CHEMICAL ABSTRACTS, vol. 117, no. 15, 12 October 1992, Columbus, Ohio, US; abstract no. 148347y, Y UJI, H SUGIUCHI, H OKABE: "Evaluation of serum troponin T measurement in acute myocardial infarction" XP002086290 * |
E W NIELSEN, H T JOHANSEN, B STRAUME, T E MOLLNES: "Effect of time, temperature and additives on a functional assay of C1 inhibitor", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 173, 1994, pages 245 - 251, XP002086286 * |
P O COLLINSON, S THOMAS, L SIU, P VASEDUVA, P J STUBBS, R CANEPA-ANSON: "Rapid troponin T measurement in whole blood for detection of myocardial damage", ANNALS OF CLINICAL BIOCHEMISTRY, vol. 32, no. 5, September 1995 (1995-09-01), pages 454 - 458, XP002086285 * |
W L ROBERTS, C B CALCOTE, B K DE, V HOLMSTROM, C NARLOCK, F S APPLE: "Prevention of Analytical False-Positive Increases of Cardiac Troponin I on the Stratus II analyser", CLINICAL CHEMISTRY, vol. 43, no. 5, May 1997 (1997-05-01), pages 860 - 861, XP002086289 * |
YOSHINORI UJI ET AL., RINSHO BYORI, vol. 40, no. 7, 1992, pages 775 - 782 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004510161A (ja) * | 2000-09-25 | 2004-04-02 | アボット・ラボラトリーズ | 高分子ポリカチオンを用いることにより、特異的結合アッセイにおける血清または血漿含有アッセイ試料の干渉を減少させるための方法及びキット |
WO2002063302A1 (fr) * | 2001-02-07 | 2002-08-15 | Immunomatrix Inc. | Technique permettant de reduire l'interference de l'heparine dans des essais diagnostic de la troponine cardiaque |
US10627393B2 (en) | 2012-07-31 | 2020-04-21 | Sekisui Medical Co., Ltd. | Latex agglutination inhibition immunoassay |
CN108291911A (zh) * | 2015-10-30 | 2018-07-17 | 美迪恩斯生命科技株式会社 | 凝血酶-抗凝血酶复合体的测定试剂及测定方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1051623A1 (fr) | 2000-11-15 |
FR2774473B1 (fr) | 2000-05-12 |
FR2774473A1 (fr) | 1999-08-06 |
JP2002502979A (ja) | 2002-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3357163B2 (ja) | 免疫学的測定用トロポニン安定化組成物および安定化法 | |
JP7166364B2 (ja) | C反応性タンパク質を全域検出する方法及び対応するキット | |
EP0804736B1 (fr) | Procede de dosage ultrasensible de la troponine i cardiaque | |
JP3646097B2 (ja) | 前進性グリコシル化終末産物を含有しない特異的結合アッセイの試薬および固相成分 | |
WO1999040442A1 (fr) | Dosage des troponines sans interferences dues a l'heparine | |
JP2010513917A (ja) | ロングペントラキシンptx3の血漿レベルを測定するための方法 | |
WO2005124344A2 (fr) | Procede de detection d'anticorps anti-transglutaminase dans un echantillon de salive | |
US8900882B2 (en) | Method of assaying complex and kit to be used therefor | |
EP0063064B1 (fr) | Réactif pour le dosage radio-ou enzymo immunologique des IgE | |
FR2779526A1 (fr) | Nouveau procede de dosage de la troponine i cardiaque | |
EP0757795B1 (fr) | Procede de detection de produits finaux de glycolysation avancee dans l'hemoglobine | |
JP4877578B2 (ja) | 抗原の測定法およびそれに用いるキット | |
FR2709492A1 (fr) | Méthode d'immunodosage spécifique de la glutathion peroxydase plasmatique humaine, kit pour sa mise en Óoeuvre, oligopeptides et anticorps spécifiques de la méthode . | |
JP5294257B2 (ja) | ヘモグロビンの測定方法および測定用キット | |
EP0164780A1 (fr) | Procédé de dosage immunologique d'une substance dans un échantillon liquide | |
JPH07198721A (ja) | 免疫測定用緩衝液 | |
JP4455688B2 (ja) | 分析物遊離段階を可能にするアッセイ用表面 | |
JP2000193666A (ja) | 吸収剤を用いた酵素免疫測定方法及び試薬 | |
FR3067814A1 (fr) | Procede d'application, sur un support solide, d'au moins un partenaire de liaison a une molecule | |
JPH0373857A (ja) | リウマチ患者のIgG上のガラクトース欠損を測定する方法 | |
CA2210166C (fr) | Procede de dosage ultrasensible de la troponine i cardiaque | |
CN113176407A (zh) | 一种定量检测Lp-PLA2含量的试剂盒 | |
EP0603061A1 (fr) | Test de pyrogénicité et kit de mise en oeuvre | |
JP2023171257A (ja) | 交叉反応を抑制した葉酸測定方法 | |
FR3132356A1 (fr) | Méthode d’analyse de l’activation plaquettaire héparine dépendante |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999901673 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09601315 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999901673 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999901673 Country of ref document: EP |